RA patients have a high rate of heart failure and worse prognosis once HF develops, MR supports RA as a causal HF risk factor, and IL15RA emerged as a shared causal target that dioscin binds and downregulates, phenocopying IL15RA silencing in endothelial cells and macrophages.
The rate of heart failure is high among patients with rheumatoid arthritis in national survey data, and RA patients with HF have a worse prognosis.
Two-sample Mendelian randomization identified rheumatoid arthritis as a significant risk factor for heart failure.
IL15RA was identified as a shared causal target linking RA and HF.
IL15RA silencing suppressed TNF-α-induced ICAM-1 in endothelial cells and reduced M1 (CD86+) macrophage polarization.
MIF signaling was strongly implicated in the crosstalk between endothelial cells and macrophages.
Dioscin, a yam-derived saponin, bound IL15RA and reduced its expression in endothelial cells and macrophages, phenocopying IL15RA silencing.
The study proposes IL15RA as a therapeutic target and dioscin as a dietary phytochemical with anti-inflammatory potential for cardiac comorbidity in RA.
This study looked at why people with rheumatoid arthritis (RA), an autoimmune joint disease, are more likely to develop heart failure. Using a large US health survey (about 2,900 people), the researchers found heart failure was common among people with RA and that those with both conditions had worse outcomes. Genetic analysis (Mendelian randomization) also supported the idea that RA itself raises the risk of heart failure. The team then searched for shared biological drivers and identified a gene/protein called IL15RA. In lab experiments, turning down IL15RA reduced inflammatory signals in blood vessel lining cells and reduced the shift of immune cells (macrophages) toward an inflammatory state. They also found that a plant compound from yams, dioscin, attached to IL15RA and lowered its levels in both cell types, producing effects similar to silencing the gene. This research suggests IL15RA may be a link between RA and heart failure and a possible treatment target. However, the dioscin findings come from cell experiments and computational analyses, not human trials, so it is not yet known whether dioscin would protect the heart in people with RA.
Geng Q, Wen C, Yang M, Zhou Y, Yang M, Geng Q, et al.. (2026). Integrative population genetics and multi-omics reveal IL15RA as a shared pathogenic hub in rheumatoid arthritis-related heart failure.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1956897